Miromatrix Entered into a Collaborative Research Agreement with Baxter to Test Bioengineered Liver Replacement Therapy
Shots:
- Baxter collaborated with Miromatrix to help advance bioengineered replacement organs for patients suffering from acute liver failure
- Miromatrix’s liver replacement therapy, miroliverELAP combines Miromatrix’s single-use bioengineered liver with Baxter’s PrisMax system. An IND application for miroliverELAP was submitted to the US FDA in Nov 2022 and aimed to begin a P-I clinical trial using miroliverELAP to treat patients with ALF
- MiroliverELAP provides external support to the patient’s native liver as a bridge-to-transplant or bridge-to-recovery, potentially helping to avoid a liver transplant while Baxter’s PrisMax system helps to deliver continuous renal replacement therapy and other therapies
Ref: Businesswire | Image: Miromatrix
Related News:- Baxter to Acquire Hillrom for ~$10.5B
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
